Format

Send to

Choose Destination
Indian J Med Microbiol. 2012 Oct-Dec;30(4):448-52. doi: 10.4103/0255-0857.103767.

Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: Monotherapy or combination therapy?

Author information

1
Department of Infectious diseases and Clinical Microbiology, Ministry of Health Okmeydani Training and Research Hospital, Istanbul, S.B. Okmeydani Egitim ve Arastirma Hastanesi Sisli-Istanbul, Turkey.

Abstract

PURPOSE:

To evaluate the outcomes of the patients who were infected with colistin-only-susceptible (COS) Acinetobacter baumannii and treated with either colistin monotherapy or colistin combined therapy.

MATERIALS AND METHODS:

This retrospective case-control study was conducted in the training and research hospital with an 800 beds between August 2008 and December 2011. The patients, who were infected with COS A. baumannii and received either colistin monotherapy or colistin combined therapy, were included into the study.

RESULTS:

In total, 51 patients fulfilling study criteria were evaluated. Colistin monotherapy was found effective as much as colistin combined therapy in terms of clinical and microbiological responses in patients with ventilator associated pneumonia (VAP) and also in patients with blood stream infections.

CONCLUSION:

Although there is no randomised controlled study yet, colistin monotherapy and colistin combined therapy are likely to achieve similar treatment responses rates. Heteroresistant strains can emerge in patients who receive colistin monotherapy.

PMID:
23183471
DOI:
10.4103/0255-0857.103767
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center